ÎÛÎÛÂþ®‹ companies are harnessing cell & gene therapy to address complex medical conditions and advance therapeutic options. Innovations like recombinant AAV vectors for glioblastoma, peptide-modified AAV capsids for muscle targeting, and oral delivery systems for oligonucleotides highlight the field’s growth. Despite a recent decline in patents and deals, these technologies are poised to significantly enhance patient outcomes and expand market opportunities. GlobalData’s cell & gene therapy market report provides comprehensive analysis of the market.
This article presents a quarterly round-up of the latest trends in the pharmaceutical industry regarding cell & gene therapy. It provides an overview of recent developments in cell & gene therapy-related deals, talent acquisition, and patent filings within the pharmaceutical industry.
Diverse applications of cell & gene therapy in pharmaceutical industry
Pharma companies are actively leveraging innovative cell & gene therapy technologies to enhance their therapeutic offerings and address complex medical conditions. Recent patents highlight advancements such as a recombinant AAV vector for glioblastoma treatment, which could improve immuno-oncology applications (Chan Zuckerberg Biohub). Additionally, a peptide-modified AAV capsid aims to enhance muscle-targeting capabilities for gene therapy (Genethon SA). Civi Biopharma Inc. is focusing on oral delivery systems for oligonucleotides, potentially increasing accessibility and patient compliance. Furthermore, UnitedHealth Group Inc. is developing extracellular vesicles from umbilical cord mesenchymal cells for treating autoimmune diseases, showcasing the versatility of cell-based therapies. These innovations position these companies to significantly improve patient outcomes and expand their market presence in the evolving field of cell & gene therapy.
The industry experienced a 19% decline in the number of cell & gene therapy-related patent applications in Q2 2024 compared with the previous quarter. On an annual basis, the number of cell & gene therapy-related patent applications in the pharmaceutical industry witnessed a drop of 11% compared with Q2 2023.
Strategic deal trends in cell & gene therapy in pharmaceutical industry
ÎÛÎÛÂþ®‹ companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in cell & gene therapy. These investments aim to secure lucrative deals with partners and position themselves at the forefront of industry advancements. Some of the recent deals underscore the importance of cell & gene therapy in the pharmaceutical industry.
In Q2 2024, the number of cell & gene therapy-related deals in the pharmaceutical industry declined by 38% compared with Q2 2023. On a quarterly basis, there was 18% drop in the number of deals in Q2 2024 compared with the previous quarter.
Impact on hiring
In terms of new job posting, in Q2 2024, the pharmaceutical industry experienced a 10% drop compared with the previous quarter. On an annual basis, job postings also declined by 19%. Notably, management occupations, with a share of 27%, emerged as the top cell & gene therapy-related job roles within the pharmaceutical industry in Q2 2024, with new job postings drop by 10% quarter-on-quarter. Life, physical, and social science occupations came in second with a share of 23% in Q2 2024, with new job postings rising by 13% over the previous quarter. The other prominent cell & gene therapy roles include computer and mathematical occupations with a 4% share in Q2 2024, and healthcare practitioners and technical occupations with a 3% share of new job postings.
, Ferring ÎÛÎÛÂþ®‹s, AstraZeneca, Genscript Biotech, and WuXi AppTec are among the top companies leading in cell & gene therapy hiring within the pharmaceutical industry.
Countries driving adoption of cell & gene therapy in pharmaceutical industry
The US is the leading country in cell & gene therapy adoption within the pharmaceutical industry, boasting the highest number of cell & gene therapy-related patents, jobs, and deals. Meanwhile, Germany, Australia, Japan and South Korea also maintain significant positions in cell & gene therapy adoption within the pharmaceutical industry.
In conclusion, while the industry faces a temporary slowdown, the advancements in cell & gene therapy continue to drive significant potential for breakthroughs and market expansion. Companies remain committed to pushing the boundaries of treatment and achieving transformative results.
To further understand GlobalData's analysis on cell & gene therapy in the pharmaceutical industry,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
